Grufity logoGrufity logo

Fulcrum Therapeutics, Inc. Stock Research

FULC

12.87USD+0.30(+2.39%)Market Closed

Market Summary

USD12.87+0.30
Market Closed
2.39%

FULC Alerts

FULC Stock Price

FULC RSI Chart

FULC Valuation

Market Cap

669.9M

Price/Earnings (Trailing)

-6.25

Price/Sales (Trailing)

62.52

Price/Free Cashflow

-6.59

FULC Price/Sales (Trailing)

FULC Profitability

Return on Equity

-48.43%

Return on Assets

-43.27%

Free Cashflow Yield

-15.16%

FULC Fundamentals

FULC Revenue

Revenue (TTM)

10.7M

Revenue Y/Y

-76.03%

Revenue Q/Q

-37.14%

FULC Earnings

Earnings (TTM)

-107.2M

Earnings Y/Y

-14.59%

Earnings Q/Q

30.33%

Price Action

52 Week Range

3.2124.79
(Low)(High)

Last 7 days

1.9%

Last 30 days

94.7%

Last 90 days

137.0%

Trailing 12 Months

11.7%

FULC Financial Health

Current Ratio

15.49

FULC Investor Care

Shares Dilution (1Y)

28.44%

Diluted EPS (TTM)

-2.56

Peers (Alternatives to Fulcrum Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
442.1B
96.0B
-4.77% 1.21%
23.08
4.6
5.02% 7.14%
308.1B
29.2B
-6.33% 46.49%
51.07
10.54
5.34% 1.02%
267.0B
59.0B
-5.13% 34.98%
17.49
4.53
27.84% 112.03%
245.5B
99.9B
-13.80% -15.92%
8.25
2.46
45.01% 53.21%
154.0B
46.7B
0.64% 15.96%
23.07
3.3
2.79% 223.53%
MID-CAP
5.0B
4.4B
10.03% -0.57%
-46.66
1.14
1.80% 57.67%
2.2B
659.0M
13.79% 40.18%
57.51
3.29
16.78% -53.92%
SMALL-CAP
1.9B
613.6M
24.42% -38.51%
-3.79
3.14
37.73% -7.19%
1.6B
3.1M
23.90% 79.89%
-5.08
503.44
-77.09% -12.24%
1.4B
-
33.79% -57.23%
-0.46
1.95
-4.11% -144.36%
1.2B
23.5M
12.85% 73.07%
-14.2
49.6
243.57% -1.04%
942.1M
112.7M
- -24.55%
-4.21
8.36
45.53% 40.26%
885.5M
-
-2.61% -19.99%
2.65
2.34
10.49% -16.07%
298.8M
49.7M
46.97% -25.95%
-5.03
6.01
28.95% 32.80%
94.1M
2.6B
-43.99% -88.43%
-0.03
0.04
-13.88% -4855.92%

Financials for Fulcrum Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-25.9%10,715,00014,467,00016,966,00019,163,00018,330,000
Operating Expenses-0.1%118,862,000119,029,000106,975,000100,217,00093,612,000
  S&GA Expenses2.7%41,269,00040,190,00035,777,00030,516,00026,678,000
  R&D Expenses-2.2%77,128,00078,839,00071,198,00069,701,00066,934,000
Interest Expenses-0----
Net Income-2.9%-107,220,000.00-104,198,000.00-89,776,000.00-80,847,000.00-75,083,000.00
Net Income Margin-38.9%-10.01-7.20-5.29-4.22-
Free Cahsflow-5.4%-101,578,000.00-96,353,000.00-86,055,000.00-80,191,000.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets26.9%248195220235256
  Current Assets30.7%228174200226246
    Cash Equivalents126.5%9140333565
  Net PPE-5.9%78878
Liabilities-23.5%2634312325
  Current Liabilities-33.6%1522181921
Shareholder's Equity37.7%221161189212231
  Retained Earnings-6.5%-386.20-362.46-328.39-302.47-278.98
  Additional Paid-In Capital16.1%608524519514510
Accumulated Depreciation6.5%109988
Shares Outstanding26.9%5241414141
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-5.7%-99.21-93.90-84.36-78.48-76.45
  Share Based Compensation5.3%141313119
Cashflow From Investing161.4%40-64.68-122.42-129.67-135.17
Cashflow From Financing-40.1%85142139187192

Risks for FULC

What is the probability of a big loss on FULC?

97.8%


Probability that Fulcrum Therapeutics stock will be more than 20% underwater in next one year

97.8%


Probability that Fulcrum Therapeutics stock will be more than 30% underwater in next one year.

94.6%


Probability that Fulcrum Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does FULC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Fulcrum Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for FULC

Cumulative Returns on FULC

-9.6%


3-Year Cumulative Returns

Which funds bought or sold FULC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-25
Lindbrook Capital, LLC
sold off
-100
-2,000
-
-%
2023-01-24
Bank Julius Baer & Co. Ltd, Zurich
added
1.6
-6,000
62,000
-%
2023-01-24
NATIONAL BANK OF CANADA /FI/
unchanged
-
-657
3,343
-%
2023-01-23
Allspring Global Investments Holdings, LLC
sold off
-100
-74,000
-
-%
2023-01-18
COUNTRY TRUST BANK
unchanged
-
-24,246
219,754
0.01%
2023-01-13
Allworth Financial LP
sold off
-100
-1,000
-
-%
2023-01-10
SOA Wealth Advisors, LLC.
new
-
5,824
5,824
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
25.42
192,000
372,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
sold off
-100
-
-
-%
2022-11-16
BNP PARIBAS ARBITRAGE, SNC
new
-
77,268
77,268
-%

1–10 of 45

Latest Funds Activity

Are funds buying FULC calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own FULC
No. of Funds

Fulcrum Therapeutics News

Nasdaq

Wall Street Analysts Believe Fulcrum Therapeutics, Inc. (FULC ....

Nasdaq,
2 days ago

Marketing Sentinel

Investing.com UK

Defense World

Benzinga

BioWorld Online

Financings for Jan. 18, 2023.

BioWorld Online,
10 days ago

Schedule 13G FIlings of Fulcrum Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 23, 2023
cowen financial products llc
615%
1,367,759
SC 13G/A
Jan 06, 2023
ra capital management, l.p.
18.6%
9,686,628
SC 13G/A
Aug 26, 2022
ra capital management, l.p.
13.45%
7e+06
SC 13G
Jun 22, 2022
point72 asset management, l.p.
4.3%
1,750,000
SC 13G
Mar 10, 2022
adage capital partners gp, l.l.c.
5.29%
2,150,000
SC 13G
Mar 09, 2022
cowen financial products llc
5.16%
2,096,890
SC 13G
Feb 14, 2022
third rock ventures iii, l.p.
9.8%
3,962,202
SC 13G/A
Feb 14, 2022
rtw investments, lp
9.5%
3,866,872
SC 13G/A
Feb 11, 2022
suvretta capital management, llc
5.9%
2,375,571
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

FULC Fair Value

Recent SEC filings of Fulcrum Therapeutics

View All Filings
Date Filed Form Type Document
Jan 24, 2023
4
Insider Trading
Jan 23, 2023
SC 13G/A
Major Ownership Report
Jan 18, 2023
424B5
Prospectus Filed
Jan 18, 2023
8-K
Current Report
Jan 17, 2023
424B5
Prospectus Filed
Jan 17, 2023
8-K
Current Report
Jan 13, 2023
4
Insider Trading
Jan 06, 2023
4
Insider Trading
Jan 06, 2023
SC 13G/A
Major Ownership Report
Jan 04, 2023
8-K
Current Report

Latest Insider Trading transactions for FULC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-20
RA CAPITAL MANAGEMENT, L.P.
bought
25,000,000
13
1,923,080
-
2023-01-13
Gould Robert J
sold
-101,490
15
-6,766
interim president & ceo
2023-01-04
RA CAPITAL MANAGEMENT, L.P.
bought
1,314,810
7.27606
180,703
-
2022-12-27
RA CAPITAL MANAGEMENT, L.P.
bought
24,509.9
5.9941
4,089
-
2022-12-19
RA CAPITAL MANAGEMENT, L.P.
bought
582,814
5.8997
98,787
-
2022-12-16
RA CAPITAL MANAGEMENT, L.P.
bought
7,269,830
5.4195
1,341,420
-
2022-12-15
RA CAPITAL MANAGEMENT, L.P.
bought
1,302,470
5.495
237,029
-
2022-12-14
RA CAPITAL MANAGEMENT, L.P.
bought
4,501,570
5.4591
824,600
-
2022-12-13
Third Rock Ventures III, L.P.
sold
-
-
-2,000,000
-
2022-06-07
Gould Robert J
sold
-577,895
8.0898
-71,435
-

1–10 of 50

Bryan E. Stuart
100
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FULC Income Statement

2022-09-30
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Collaboration revenue$ 1,183$ 4,935$ 5,657$ 14,105
Operating expenses:    
Research and development15,36617,07758,21650,789
General and administrative9,7078,62831,56420,811
Restructuring expenses46504650
Total operating expenses25,53825,70590,24571,600
Loss from operations(24,355)(20,770)(84,588)(57,495)
Other income, net61754852132
Net loss$ (23,738)$ (20,716)$ (83,736)$ (57,363)
Net loss per share, basic$ (0.51)$ (0.57)$ (1.97)$ (1.71)
Net loss per share, diluted$ (0.51)$ (0.57)$ (1.97)$ (1.71)
Weighted-average common shares outstanding, basic46,21336,60642,60333,603
Weighted-average common shares outstanding, diluted46,21336,60642,60333,603
Comprehensive loss:    
Net loss$ (23,738)$ (20,716)$ (83,736)$ (57,363)
Other comprehensive (loss) gain:    
Unrealized gain (loss) on marketable securities147(78)(524)(85)
Total other comprehensive loss147(78)(524)(85)
Comprehensive loss$ (23,591)$ (20,794)$ (84,260)$ (57,448)

FULC Balance Sheet

2022-09-30
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 90,938$ 35,412
Marketable securities130,851182,750
Accounts receivable132,500
Unbilled accounts receivable7901,137
Prepaid expenses and other current assets5,1354,199
Total current assets227,727225,998
Property and equipment, net7,3757,368
Operating lease right-of-use assets9,5130
Restricted cash1,0921,092
Other assets2,098542
Total assets247,805235,000
Current liabilities:  
Accounts payable2,7284,788
Accrued expenses and other current liabilities8,0399,231
Deferred revenue, current portion1,3894,711
Operating Lease Liability, current2,5430
Deferred lease incentive, current portion0469
Total current liabilities14,69919,199
Operating lease liability, excluding current portion11,4950
Other liabilities, excluding current portion197
Deferred rent, excluding current portion1,680
Deferred lease incentive, excluding current portion02,582
Total liabilities26,39123,461
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding00
Common stock, $0.001 par value; 200,000,000 shares authorized; 41,008,205 and 40,636,398 shares issued as of June 30, 2022 and December 31, 2021, respectively; 41,008,205 and 40,626,224 shares outstanding as of June 30, 2022 and December 31, 2021, respectively5241
Treasury stock, at cost; no shares00
Additional paid-in capital608,486514,362
Accumulated other comprehensive loss(921)(397)
Accumulated deficit(386,203)(302,467)
Total stockholders’ equity221,414211,539
Total liabilities and stockholders’ equity$ 247,805$ 235,000